Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure

Cardiovascular Drugs and Therapy

Volumn 25, Issue SUPPL. 1, 2011, Pages

  Onogawa, Toshiyuki ^a   Sakamoto, Yuki ^a   Nakamura, Shigeki ^a   Nakayama, Sunao ^a   Fujiki, Hiroyuki ^a   Yamamura, Yoshitaka ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Heart failure; Hemodynamics; Neurohormones; Vasopressin V 2 receptor antagonist

Indexed keywords

ARGIPRESSIN; FUROSEMIDE; RENIN; SODIUM; TOLVAPTAN;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIURETIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EXPERIMENTAL DOG; FLUID BALANCE; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HORMONE ACTION; HORMONE BLOOD LEVEL; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALURESIS; SODIUM BLOOD LEVEL;

ANIMALS; ARGININE VASOPRESSIN; ATRIAL NATRIURETIC FACTOR; BENZAZEPINES; BLOOD PRESSURE; BODY WEIGHT; CHLORIDES; DISEASE MODELS, ANIMAL; DIURETICS; DOGS; FUROSEMIDE; HEART FAILURE; KIDNEY; MALE; POTASSIUM; RECEPTORS, VASOPRESSIN; RENIN; SODIUM;

EID: 83655212321     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6350-4     Document Type: Article

References (30)

1. McInnes G. Diuretics. In: Dukes M, editor. Meyler's side effects of drugs. Amsterdam: Elsevier Science B.V; 1996. p. 558-82.
2. HA Cooper DL Dries CE Davis YL Shen MJ Domanski 1999 Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction Circulation 100 1311 5 10491376 1:STN:280:DyaK1MvitlKiuw%3D%3D (Pubitemid 29440124)
3. M Domanski J Norman B Pitt M Haigney S Hanlon E Peyster 2003 Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD) J Am Coll Cardiol 42 705 8 12932605 10.1016/S0735-1097(03)00765-4 1:CAS:528:DC%2BD3sXnsFerurY%3D (Pubitemid 37000189)
4. WH Lee M Packer 1986 Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure Circulation 73 257 67 3002660 10.1161/01.CIR.73.2.257 1:STN:280:DyaL287gs1Kmsg%3D%3D (Pubitemid 16127402)
5. GS Francis RM Siegel SR Goldsmith MT Olivari TB Levine JN Cohn 1985 Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis Ann Intern Med 103 1 6 2860833 1:STN:280:DyaL2M3itlCrsA%3D%3D (Pubitemid 15068490)
6. IS Anand GS Kalra P Harris, et al. 1991 Diuretics as initial and sole treatment in chronic cardiac failure Cardioscience 2 273 8 1760518 1:STN:280:DyaK387gtlWmtQ%3D%3D
7. Colucci W. Pathophysiology of heart failure. In: Brounwald E, editor. Heart Disease. Philadelphia: WB Saunders Co.; 1997. p. 394-420.
8. K Kondo H Ogawa H Yamashita, et al. 1999 7-Chloro-5-hydroxy-1-[2-methyl- 4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist Bioorg Med Chem 7 1743 54 10482466 10.1016/S0968-0896(99)00101-7 1:CAS:528:DyaK1MXlslWgtLw%3D (Pubitemid 29347138)
9. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 860 7 9864265 1:CAS:528:DyaK1MXjvVShsw%3D%3D (Pubitemid 29131593)
10. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 292 288 94 10604960 1:CAS:528:DC%2BD3cXhslGktg%3D%3D (Pubitemid 30026383)
11. M Gheorghiade I Niazi J Ouyang, et al. 2003 Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial Circulation 107 2690 6 12742979 10.1161/01.CIR.0000070422.41439.04 1:CAS:528:DC%2BD3sXjvFKjtbk%3D (Pubitemid 36667242)
12. M Gheorghiade WA Gattis CM O'Connor, et al. 2004 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 1963 71 15113814 10.1001/jama.291.16.1963 1:CAS:528:DC%2BD2cXjs1ajsb8%3D (Pubitemid 38544277)
13. LC Costello-Boerrigter WB Smith G Boerrigter, et al. 2006 Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Am J Physiol Renal Physiol. 290 F273 8 16189291 10.1152/ajprenal.00195.2005 1:CAS:528:DC%2BD28XhsFKit7Y%3D (Pubitemid 43724981)
14. C Brun 1950 Thiosulfate determination in kidney function tests; a simple method for the determination of thiosulfate in blood and urine J Lab Clin Med. 35 152 4 15400637 1:CAS:528:DyaG3cXhslyktw%3D%3D
15. WD Davidson MA Sackner 1963 Simplification of the anthrone method for the determination of inulin in clearance studies J Lab Clin Med. 62 351 6 14060462 1:CAS:528:DyaF2cXht1Sgtg%3D%3D
16. PW Armstrong TP Stopps SE Ford AJ de Bold 1986 Rapid ventricular pacing in the dog: pathophysiological studies of heart failure Circulation 74 1075 84 2945673 10.1161/01.CIR.74.5.1075 1:STN:280:DyaL2s%2FivVKnsQ%3D%3D (Pubitemid 17174956)
17. AJ Riegger G Liebau 1982 The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure Clin Sci 62 465 9 7075144 1:CAS:528:DyaL38XksFentLk%3D (Pubitemid 12127225)
18. MT Kearney KA Fox AJ Lee, et al. 2002 Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure J Am Coll Cardiol 40 1801 8 12446064 10.1016/S0735-1097(02)02490-7 (Pubitemid 35341959)
19. G Giebisch 1998 Renal potassium transport: mechanisms and regulation Am J Physiol Renal Physiol. 274 F817 33 1:CAS:528:DyaK1cXjsV2jtLg%3D
20. + secretion Am J Physiol Renal Physiol. 278 F809 16 10807593 1:CAS:528:DC%2BD3cXjvFahurw%3D
21. E Steiness KH Olesen 1976 Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy Br Heart J. 38 167 72 1259829 10.1136/hrt.38.2.167 1:STN:280:DyaE287mtV2ksA%3D%3D
22. GL Robertson 1983 Thirst and vasopressin function in normal and disordered states of water balance J Lab Clin Med. 101 351 71 6338137 1:CAS:528:DyaL3sXhsFGht7w%3D (Pubitemid 13164262)
23. FL Dunn TJ Brennan AE Nelson GL Robertson 1973 The role of blood osmolality and volume in regulating vasopressin secretion in the rat J Clin Invest 52 3212 9 4750450 10.1172/JCI107521 1:CAS:528:DyaE2cXlvVSquw%3D%3D
24. BC Wang WD Sundet MO Hakumaki PG Geer KL Goetz 1984 Cardiac receptor influences on the plasma osmolality-plasma vasopressin relationship Am J Physiol 246 H360 8 6703073 1:CAS:528:DyaL2cXhsFWgsbs%3D
25. TK Keeton WB Campbell 1980 The pharmacologic alteration of renin release Pharmacol Rev 32 81 227 7012850 1:CAS:528:DyaL3MXitVahtrs%3D
26. Consensus recommendations for the management of chronic heart failure 1999 On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure Am J Cardiol 83 1A 38 10.1016/S0002-9149(98)00850-9 (Pubitemid 29079601)
27. JE Udelson C Orlandi J Ouyang, et al. 2008 Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial J Am Coll Cardiol 52 1540 5 19007589 10.1016/j.jacc.2008.08.013 1:CAS:528:DC%2BD1cXhtlahtbjK
28. M Naitoh H Suzuki M Murakami, et al. 1994 Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs Am J Physiol 267 H2245 54 7810724 1:CAS:528:DyaK2MXivFGluro%3D
29. LM Burrell PA Phillips J Risvanis RK Chan KL Aldred CI Johnston 1998 Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol 275 H176 82 9688911 1:CAS:528:DyaK1cXkvFaru7o%3D
30. M Takeuchi JD Lee H Shimizu T Ueda 2006 Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats Int J Cardiol 108 231 6 16002161 10.1016/j.ijcard.2005.05.009 (Pubitemid 43330619)